|
May 9
|
Summit Therapeutics Inc. (SMMT): Among the Best Cancer Stocks to Invest in for Long-Term Gain
|
|
May 7
|
Can Summit Therapeutics Stock Double Your Money?
|
|
May 6
|
Wall Street Analysts Predict a 33.4% Upside in Summit Therapeutics (SMMT): Here's What You Should Know
|
|
May 4
|
Why Summit Therapeutics Inc. (SMMT) Soared Last Week
|
|
Apr 26
|
Akeso survival data for ivonescimab misses expectations, STAT says
|
|
Apr 25
|
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today
|
|
Apr 25
|
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China
|
|
Apr 24
|
Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025
|
|
Apr 24
|
Akeso and Summit notch another Phase III win with their Keytruda competitor
|
|
Apr 23
|
Why Summit Therapeutics Inc. (SMMT) Went Up On Wednesday
|
|
Apr 23
|
BioNTech Surges On Summit's Coattails. But Can They Take On Merck?
|
|
Apr 23
|
Why Summit Therapeutics Rocketed Double-Digits Today
|
|
Apr 23
|
Why Is Summit Therapeutics Stock Soaring On Wednesday?
|
|
Apr 23
|
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China
|
|
Apr 23
|
This Company's Co-CEOs Just Bought More Shares. Should You?
|
|
Apr 15
|
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Monday?
|
|
Apr 14
|
Summit Therapeutics (NasdaqGM:SMMT) Welcomes Robert LaCaze As New Chief Commercial Officer
|
|
Apr 14
|
Here's Why Summit Therapeutics Stock Soared 15% on Friday
|
|
Apr 12
|
Why Summit Therapeutics Inc. (SMMT) Soared Last Week?
|
|
Apr 12
|
3 Magnificent Stocks That Could Double or More by 2030
|